Switch to
More onapp

How to use scorecard? Learn more

Glenmark Pharmaceuticals Ltd

GLENMARK
Health CarePharmaceuticals
MidcapWith a market cap of ₹39,871 cr, stock is ranked 212
Moderate RiskStock is 2.60x as volatile as Nifty
1,412.950.40 (-0.03%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹39,871 cr, stock is ranked 212
Moderate RiskStock is 2.60x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
-26.55
PB RatioPB Ratio
4.05
Dividend YieldDiv. Yield
0.18%
Sector PESector PE
44.49
Sector PBSector PB
5.96
Sector Div YldSctr Div Yld
0.56%

Forecast & RatingsDetailed Forecast 

55%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

Brands

Glenmark Pharma

Pharmaceutical company

Investor PresentationView older 

Sep 21, 2023

PDF
View Older Presentations

Brands

Glenmark Pharma

Pharmaceutical company

Financial TrendFinancial statements 

202120222023202411.0412.4713.3113.050.970.940.30-1.50
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnJul 17, 2024

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 17, 2024, titled "Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg". | Download

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 17, 2024, titled "Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg". | Download

Press Release 
Announced OnJun 12, 2024

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 12, 2024, titled "Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)". | Download

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 12, 2024, titled "Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)". | Download

Cash Dividend 
Ex. DateSep 18, 2023

Final • Div/Share: ₹ 2.5

See all events